Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2024

Accounting Policies [Abstract]

Schedule of Disaggregation of Revenue

Revenue from VTE and Emerging Therapies is as follows (in thousands):

	Three Months Ended March 31,
	2024		2023
VTE	$	137,193	$	114,058
Emerging Therapies	6,001		2,109
Total Revenue	$	143,194	$	116,167

Revenue from the Company's products by geographic area, based on the location where title transfers, is as follows (in thousands):

	Three Months Ended March 31,
	2024		2023
United States	$	133,683	$	111,846
International	9,511		4,321
Total revenue	$	143,194	$	116,167

Schedule of Cash Flow, Supplemental Disclosures

Supplemental cash flow information includes the following (in thousands):

	Three Months Ended March 31,
	2024		2023
Supplemental disclosures of cash flow information:
Cash paid for income taxes	$	245	$	104
Cash paid for interest	$	57	$	32
Noncash investing and financing:
Lease liabilities arising from obtaining new right-of-use assets	$	—	$	1,030
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	66,707	$	56,562
Restricted cash	500		—
Total cash, cash equivalents and restricted cash as shown in the statement of cash flows	$	67,207	$	56,562